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Abstract
Background: Implementation of sputum Gram stain in the initial assessment of community-acquired pneumonia
(CAP) patients is still controversial. We performed a systematic review and meta-analysis to investigate the usefulness of
sputum Gram stain for defining the etiologic diagnosis of CAP in adult patients.
Methods: We systematically searched the Medline, Embase, Science Direct, Scopus and LILACS databases for full-text
articles. Relevant studies were reviewed by at least three investigators who extracted the data, pooled them using a
random effects model, and carried out quality assessment. For each bacterium (Streptococcus pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, and Gram-negative bacilli), pooled sensitivity, specificity, positive
and negative likelihood ratios were reported.
Results: After a review of 3539 abstracts, 20 articles were included in the present meta-analysis. The studies
included yielded 5619 patients with CAP. Pooled sensitivity and pooled specificity of sputum Gram stain were
0.59 (95% CI, 0.56–0.62) and 0.87 (95% CI, 0.86–0.89) respectively for S. pneumoniae, 0.78 (95% CI, 0.72–0.84)
and 0.96 (95% CI, 0.94–0.97) for H. influenzae, 0.72 (95% CI, 0.53–0.87) and 0.97 (95% CI, 0.95–0.99) for S. aureus, and 0.64
(95% CI, 0.49–0.77) and 0.99 (95% CI, 0.97–0.99) for Gram-negative bacilli.
Conclusion: Sputum Gram stain test is sensitive and highly specific for identifying the main causative pathogens in
adult patients with CAP.
Trial registration: This study has been registered at PROSPERO International prospective register of systematic reviews
under registration no. CRD42015015337.
Keywords: Community-acquired pneumonia, Sputum, Gram, Sensitivity, Specificity, Meta-analysis
Background
Community-acquired pneumonia (CAP) is a frequent
infection with significant morbidity and mortality, espe-
cially in extreme ages of life and in patients who have
underlying diseases [1, 2]. CAP is also related with a
high economic burden, and considerable long-term ef-
fects on quality of life and prognosis [3, 4].
Several tests are recommended to establish the causa-
tive pathogen of CAP. Although the sputum Gram stain
is a rapid, simple and low-cost method, its role in the
initial assessment of patients with CAP is still controver-
sial. Studies have raised doubts about its utility due to
the difficulty in obtaining the sample and its limited
sensitivity, and overall impact on decision-making [5],
but other authors favor its use [6]. The identification of
the causative pathogen in CAP by sputum Gram stain
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may facilitate the use of a targeted antimicrobial therapy,
thus decreasing the collateral damage (selection of drug-
resistant pathogens and the development of colonization
or infection with multidrug-resistant organisms), saving
costs and limiting the risk of adverse reactions.
The current guidelines for the management of CAP
contain a variety of recommendations for performing
sputum Gram stain [2, 7, 8]. While some of them advo-
cate its routine use, others recommend it in moderate to
severe cases, in circumstances in which it can be proc-
essed at the place where it was taken, or when it would
alter empirical therapy. Up to now, only one meta-analysis
has evaluated the accuracy of sputum Gram stain for de-
termining the causative pathogens of CAP [9], and in fact
that study focused only on pneumococcal pneumonia.
What is more, that meta-analysis was carried out nearly
two decades ago, and since then several studies analyzing
the usefulness of sputum Gram stain in CAP have been
published.
We performed a systematic review and meta-analysis
to investigate the usefulness of sputum Gram stain for
determining the etiologic diagnosis of CAP in adult
patients.
Methods
The present systematic review and meta-analysis was
performed following the guidelines for meta-analyses of
observational studies in epidemiology (MOOSE) [10].
We systematically searched the Medline, Embase, Science
Direct, Scopus and LILACS (Literatura Latino-Americana
e do Caribe de Informação em Ciências da Saúde) data-
bases for full-text articles that assessed the accuracy of
sputum Gram stain for determining the etiology of CAP
in adults. The search strategy included the terms “com-
munity-acquired pneumonia”, “sputum” and “Gram”. We
searched in the databases from their inception to
November, 2014. Two investigators independently con-
ducted the literature search.
To be eligible, the studies should have a standard
definition for CAP diagnosis, which was defined as the
evidence of a pulmonary infiltrate on chest radiography
plus at least one of the following: sputum production,
fever or hypothermia, cough, pleuritic chest pain, or
leukocytosis or leukopenia. Additionally, the sputum
Gram stains had to be compared with an independent
gold standard. Studies were rejected if they were per-
formed in immunosuppressed patients or in patients
under 16 years of age. Patients were considered im-
munosuppressed if they have neutropenia, transplant-
ation or splenectomy, HIV, immunoglobulin deficiencies,
and those who were receiving chronic corticosteroid
therapy or other immunosuppressant therapies.
The studies had to provide sufficient information for
the creation of a 2 × 2 diagnostic table. Only publications
written in English and Spanish were included. We ex-
cluded studies that evaluated animal models, editorials,
letters, reviews, abstracts from congresses and case
reports.
Procedures
We excluded non-relevant studies by the review of the
abstracts. At least three investigators reviewed poten-
tially relevant studies. They also carried out data extrac-
tion and assessed the quality of studies in a blinded
manner. Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) were used to evaluate the method-
ology quality of each study included [11]. Differences
about quality assessment or eligibility of studies were
resolved by consensus. The main features of the studies
included, such as author, year and journal of publication,
country and type of study design, sputum quality,
sputum Gram stain results, sensitivity and specificity of
sputum Gram stain to predict the causative pathogen of
CAP (S. pneumoniae, H. influenzae, S. aureus, and
Gram-negative pathogens), and sample size were ex-
tracted using a standardized form.
Statistical analysis
We extracted or estimated values for true positives, true
negatives, false negatives and false positives for each in-
cluded study and calculated sensitivity and specificity
with 95% confidence intervals (95% CI). For each causa-
tive pathogen (S. pneumoniae, H. influenzae, S. aureus,
and Gram-negatives such as K. pneumoniae and P. aerugi-
nosa), pooled sensitivity, specificity, positive and negative
likelihood ratios (LR) were reported. It has been proposed
that a positive LR > 10 or a negative LR < 0.1 is likely to
identify a clinically useful test [12]. In addition, we plotted
receiver operating characteristic curves (ROC) and calcu-
lated the area under the curve (AUC) with 95% CIs. We
constructed a summary ROC curve for describing the
relationship between sensitivity and specificity across
the studies included. Heterogeneity was evaluated by
Cochrane Q test and I2 statistics; then, we estimated
the effect size by means of fixed or random models for
homogeneous or heterogeneous studies respectively.
The AUCs were compared as described by Hanley and
MacNeil [13]. Subgroup analyses were performed in the
studies which reported “good quality sputum”, “positive
sputum Gram stain” and in which patients had not
received previous antibiotic therapy. We included in
the subgroup analysis of “good quality” sputum those
studies that used the criterion of > 25 neutrophils in
a × 100 microscopic field and few squamous epithelial
cells (< 10 in a × 100 microscopic field). We included in
the subgroup analysis of “positive sputum Gram stain”
those studies that used the criterion of the presence of
> 50% microorganisms of the same morphotype. For
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assessment of publication bias, Begg funnel plot and
Egger tests were performed. The Stata software was
used and the results were considered statistically sig-
nificant when p < 0.05.
Results
After reviewing 3539 abstracts, 113 articles were consid-
ered potentially eligible and evaluated in depth. After
full-text review, a further 93 articles were rejected and
20 were included in the present meta-analysis. Figure 1
summarizes the literature review process. All studies in-
cluded had an observational design. Table 1 shows the
main characteristics of these studies [5, 6, 14–31]. The
overall methodological quality of the studies included
was generally good, as measured by QUADAS-2 scores
(Additional file 1: Table S1). The studies included
yielded 5619 patients with CAP (range 16–1390). The
number of sputum Gram stains analyzed in the studies
varied from 16 to 404. Most studies used sputum culture
or a combination of microbiological procedures (mainly
sputum and blood cultures and urinary antigen test) as
gold standard to compare the sputum Gram stains. The
sensitivity and specificity of sputum Gram stain for
determining CAP etiology ranged from 0 to 100% (mean
of 65.7 and 84.9%, respectively). Most studies had a def-
inition for evaluating the quality of the sputum sample
and the positivity of the Gram stain, although the defini-
tions varied from study to study. The reported mortality
rates varied from 5 to 15%.
Streptococcus pneumoniae
Nineteen studies of 5395 patients with community-ac-
quired pneumococcal pneumonia were included in this
analysis (Additional file 1: Table S2). Pooled sensitivity
was 0.59 (95% CI, 0.56–0.62) and pooled specificity was
0.87 (95% CI, 0.86–0.89) (Fig. 2a). The positive LR
was 4.60 (95% CI, 2.72–7.79), negative LR was 0.39
(95% CI, 0.29–0.52) (Table 2 and Additional file 1:
Figure S1A) and the AUC was 0.86 (SE 0.02)
(Fig. 3a). There was heterogeneity among the in-
cluded studies.
Haemophilus influenzae
Eight studies were included in the analysis, comprising
3562 patients. Pooled sensitivity was 0.78 (95% CI, 0.72–
0.84) and pooled specificity was 0.96 (95% CI, 0.94–0.97)
(Fig. 2b and Additional file 1: Table S3). The positive LR
was 21.08 (95% CI, 8.32–53.40), negative LR was 0.23
(95% CI, 0.13–0.41) (Table 2 and Additional file 1:
Figure S1b) and AUC was 0.66 (SE: 0.10) (Fig. 3b).
There was heterogeneity among the included studies.
Staphylococcus aureus
Three studies that involved 1834 patients were included
in this analysis. Pooled sensitivity was 0.72 (95% CI,
0.53–0.87) and pooled specificity was 0.97 (95% CI,
0.95–0.99) (Fig. 2c and Additional file 1: Table S4).
The positive LR was 16.27 (95% CI, 2.48–106.86),
negative LR was 0.40 (95% CI, 0.30–0.53) (Table 2
Fig. 1 Flow chart of the literature review
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and Additional file 1: Figure S1C) and AUC was 0.78
(SE: 0.24) (Fig. 3c). There was heterogeneity among
the studies.
Gram-negative bacilli
Two studies were included comprising 1718 patients.
Pooled sensitivity was 0.64 (95% CI, 0.49–0.77) and
pooled specificity was 0.99 (95% CI, 0.97–0.99) (Fig. 2d
and Additional file 1: Supplementary Table 5). The posi-
tive LR was 37.49 (95% CI, 8.83–159.16), negative LR
was 0.45 (95% CI, 0.17–1.17) (Table 2 and Add-
itional file 1: Figure S1D) and AUC was 0.94 (SE: 0.03)






Fig. 2 Pooled sensitivity and specificity of sputum Gram stain in community-acquired pneumonia. a. Streptococcus pneumoniae, b. Haemophilus
influenzae, c. Staphylococcus aureus, d. Gram-negative bacilli
Del Rio-Pertuz et al. BMC Infectious Diseases          (2019) 19:403 Page 6 of 12
Subgroup analyses
“Good quality” criteria
Nine studies of pneumococcal pneumonia used the
“good quality” criteria for evaluating the sputum sam-
ples. Pooled sensitivity and pooled specificity were 0.59
and 0.93 respectively (Additional file 1: Table S6 and
Figure S2A). Four studies for H. influenzae also used
“good quality” criteria for their samples. The pooled
sensitivity was 0.74 and the pooled specificity was 0.94
(Additional file 1: Table S7 and Figure S2B).
“Positive sputum Gram stain” criteria
Regarding the percentage of microorganisms seen in the
sputum Gram stain (positive if presence of > 50% micro-
organisms of the same morphotype), we found a pooled
sensitivity of 0.50 and pooled specificity of 0.93 for
seven studies in patients with pneumococcal pneumo-
nia (Additional file 1: Supplementary Table 8 and
Additional file 1: Figure S3A). For H. influenzae, we
Table 2 Pooled likelihood ratios of sputum Gram stain in
community-acquired pneumonia
Microorganism Positive LR (95% CI) Negative LR (95% CI)
S. pneumoniae 4.60 (2.72–7.79) 0.39 (0.29–0.52)
H. influenzae 21.08 (8.32–53.40) 0.23 (0.13–0.41)
S. aureus 16.27 (2.48–106.86) 0.40 (0.30–0.56)
Gram-negative bacilli 37.49 (8.83–159.16) 0.45 (0.17–1.17)
Abbreviations: LR likelihood ratio, CI confidence interval
A B
C D
Fig. 3 Summary area under the receiver operator characteristic curves of sputum Gram stain in community acquired pneumonia. a. Streptococcus
pneumoniae, b. Haemophilus influenzae, c. Staphylococcus aureus, d. Gram-negative bacilli
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found a pooled sensitivity of 0.78 and pooled specifi-
city 0.97 (Additional file 1: Table S9 and Figure S3B).
Previous antibiotic therapy
In the studies that reported that patients with pneumo-
coccal pneumonia did not receive antibiotics before the
sample was taken, pooled sensitivity and specificity were
both 0.78 (Additional file 1: Table S10 and Figure S4A).
In the case of H. influenzae, we found a pooled sensitivity
of 0.81 and a pooled specificity of 0.96 (Additional file 1:
Table S11 and Figure S4B).
Publication bias
No publication or small-study bias was evident for the
studies that evaluated pneumococcal pneumonia (Egger
test p = 0.336), but the analysis of H. influenzae pneu-
monia indicated asymmetry and statistically significant
evidence of publication or small-study bias (Egger test
p = 0.031) (Fig. 4). For other causative pathogens of
CAP, publication bias could not be analyzed due to the
low number of studies.
Discussion
This study evaluates the usefulness of sputum Gram
stain to identify the causative pathogens in patients with
CAP. The results of our meta-analysis demonstrated that
the test is highly specific to identify S. pneumoniae, H.
influenzae, S. aureus and Gram-negative bacilli infection.
One of our most interesting findings is that the
false-negative proportion for sputum Gram stain test
ranges from 44% for S. pneumoniae to 22% for H. influ-
enzae. This result suggests that stopping antimicrobials
after a negative sputum Gram stain test result in patients
may not be appropriate. Failure to detect these causative
pathogens on sputum Gram stain does not conclusively
indicate their absence. Similarly, none of the pooled
negative LR achieved the result lower than 0.1, which is
regarded as strong evidence to reliably exclude diagno-
ses. Thus, a negative sputum Gram stain produce a
minor change in the probability of the etiologic diagno-
sis of CAP. However, a positive sputum Gram stain test
result all but confirms the causative pathogen of CAP
(with specificities ranging from 87% for S. pneumoniae
to 99% for Gram-negative bacilli). These results suggest
that, in patients with sputum production, a positive spu-
tum Gram stain can lead to appropriate initial antibiotic
selection. In this regard, the pooled positive LR was high
(above 4 for S. pneumoniae but higher than 10 for H.
influenzae, S. aureus and Gram-negative bacilli). It has
been suggested that LR values higher than 10 provides
strong evidence to rule in diagnoses in most circumstances.
The use of several microbiologic tests at the same time
(extensive diagnostic testing) to determine the causative
pathogen of CAP is controversial. There are several
arguments in its favor: for instance, its results are likely
to change antimicrobial management, it can have epide-
miologic consequences such as Legionella infection or
methicillin-resistant S. aureus, and it may provide the
frequencies of etiology and resistant microorganisms [2].
However, the main disadvantage of these tests is their
cost. The sputum Gram stain offers most of the advan-
tages of diagnostic tests in CAP and, in addition, it is a
rapid, simple and low-cost method. Similarly, the spu-
tum Gram stain can identify causative pathogens such as
S. aureus or Gram-negative bacilli that are missed by
other tests, thus increasing the likelihood of appropriate
antimicrobial use and, consequently, decreasing poor
outcomes.
Only one meta-analysis that evaluated patients with
pneumococcal pneumonia has investigated the accuracy
of the sputum Gram stain in CAP. Reed et al. [9]
concluded that the Gram stain might yield erroneous
Fig. 4 Funnel plot of studies regarding diagnostic accuracy of sputum Gram stain in community-acquired pneumonia . a. Streptococcus
pneumoniae, b. Haemophilus influenzae
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results, as its sensitivity and specificity differ substan-
tially in diverse settings. In agreement with the findings
reproduced in our meta-analysis regarding pneumococ-
cal pneumonia, Reed et al. [9] reported that the studies
included in their meta-analysis used different reference
standards for the sputum Gram stain and different defi-
nitions of positivity, and that the preparation and inter-
pretation was performed by personal from different
services in each study. These methodological inconsist-
encies may explain the variations in the sensitivity and
the specificity of the sputum Gram stain. Moreover, we
also found heterogeneity in the methodology and the
sensitivity and specificity among studies evaluating other
causative pathogens such as H. influenzae, S. aureus and
Gram-negative bacilli. On the other hand, although the
present study evaluated CAP patients, two meta-analysis
have assessed the role of bacteriological information in
improving the clinical diagnosis of ventilator-associated
pneumonia (VAP) with contradictory conclusions [32, 33].
However, Rea-Neto et al. [33] found that sputum Gram
stain could be useful in early therapeutic decisions in VAP
patients but may be influenced by prior antimicrobial use
and the causative pathogen.
To overcome these drawbacks, we performed sub-
group analyses including studies that reported “good
quality” sputum, “positive sputum Gram stain”, and in
which patients had not received prior antimicrobial ther-
apy. The sensitivity and the specificity of the sputum
Gram stain in the subgroups were comparable to those
reported in the overall analyses. It has been suggested
that the limited value of sputum Gram stain test is due
to the difficulty of obtaining samples, or more precisely
good quality samples [21, 22]. Studies have reported that
nearly half of patients with CAP have sputum produc-
tion. Moreover, although the definition of good quality is
not consistent among studies, reports of good-quality
sputum frequencies range from 14 to 71% [6, 34–37]. In
our meta-analysis, we analyzed a subgroup of patients
with “good quality” sputum, defined as > 25 neutrophils
in a × 100 microscopic field and few squamous epithelial
cells (< 10 in a × 100 microscopic field) (we stress that
some of the studies included in the meta-analysis used
different definitions of good quality sputum). The results
for sensitivity and specificity in the subgroups were simi-
lar to the results of the overall analysis. Importantly, the
studies did not report the usefulness of diagnostic tests
when poor quality sputum was obtained. Similarly, the
criteria used to define significance (the percentage of
microorganisms seen in the Gram stain) varied between
studies, but we did not detect major differences in these
subgroup analyses compared with the overall results. Fi-
nally, we detected a higher specificity of sputum Gram
stain for determining the etiology of CAP when patients
had not previously received antibiotic therapy.
Other tests also use respiratory samples for the diag-
nosis of causative pathogens of CAP. Although polymer-
ase chain reaction (PCR) testing performed in sputum
can increased microbiological yield, it has been sug-
gested that PCR is an unreliable diagnostic tool for
pneumococcal pneumonia because it cannot differentiate
between colonization and lower respiratory tract infec-
tion. In addition, other studies have found that PCR did
not show significant increase in either sensitivity or spe-
cificity in pneumococcal pneumonia, even when quanti-
fication was included [38–41]. In this regard, Stralin et
al. [42] and Kakiuchi et al. [43] obtained high sensitivity
and specificity using PCR assays for S. pneumoniae ap-
plied to sputum and nasopharyngeal aspirate samples in
patients with CAP. Moreover, protected specimen brush
and bronchoalveolar lavage quantitative cultures added
nearly 30% more microbiological documentation for
CAP compared to sputum cultures. However, import-
antly, Gram staining was indicative of the pathogen
mostly in cases where S. pneumoniae was isolated [44].
Major limitations of application of these tests include
cost and the need for specialized medical equipment.
Conversely, it has been documented that the use of
Gram staining not appear to modify health care costs of
CAP. A study found that cost reduction was more influ-
enced be price differences between targeted therapy and
non-targeted therapy [45].
Only one study has examined the impact of the use of
sputum Gram stain to guide therapeutic decision-making
on prognosis in hospitalized patients with CAP. Fukuyama
et al. (6) reported that pathogen-targeted treatment guided
by sputum Gram stain had similar efficacy and less adverse
events than empirical treatment. These results were similar
to those found in a randomized prospective open study in
which a pathogen-directed approach was compared with
empirical treatment in patients with CAP [46]. The
pathogen-directed approach used clinical presentation and
the results of a Gram stain from sputum or pleural fluid,
pneumococcal antigen detection in sputum or pleural fluid,
and L. pneumophila serogroup 1 urinary antigen detection
test to determine the antibiotic therapy. No significant dif-
ferences were found between the two treatment groups in
length of stay, 30-day mortality, or clinical failure. Side ef-
fects occurred more frequently in patients in the empirical
broad spectrum antibiotic treatment group. These results
suggest that a positive sputum Gram stain can lead to
appropriate initial antimicrobial selection without altering
clinical outcome in patients with CAP. This idea is sup-
ported by the high specificity of the test, as reported in this
meta-analysis, which allows accurate identification of the
causative pathogen. However, more investigation is needed
regarding about the potential impact of sputum Gram stain
in clinical practice, particularly in the context of antimicro-
bial stewardship programs.
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The main strength of this study is that it is the first
meta-analysis to evaluate the usefulness of sputum
Gram stain for determining the etiology of CAP due to
diverse causative pathogens. In addition, because of the
heterogeneity of the studies we also performed sub-
group analyses, which consistently reported high speci-
ficity for the sputum Gram stain test. However, it
should be note that one of the major concerns in the
sputum Gram stain is its low reliability. The interpret-
ation of the test is subjective and it is possible that dif-
fers by readers. Several limitations in our analysis
should be acknowledged. First, we restricted our search
to manuscripts published in Spanish and English. Sec-
ond, we were unable to contact all author groups to ob-
tain all relevant data in order to clarify discrepancies or
request unpublished data. Third, the results should be
interpreted cautiously because of limitations inherent
to observational studies and the heterogeneity among
studies. In addition, the methodologies used in micro-
biological work-up were heterogeneous. Fourth, a pub-
lication bias was detected for H. influenzae pneumonia,
and this analysis could not be performed for S. aureus
and Gram-negative bacilli pneumonia because of the
low number of studies included. Finally, because there
is no gold-standard for identifying the causative patho-
gen of CAP, the performance of sputum Gram stain
may have been underestimated.
Conclusion
Sputum Gram stain test is sensitive and highly specific
for identifying causative pathogens in adult patients with
CAP. Studies evaluating the impact of the use of sputum
Gram stain in treatment decision-making on outcomes
in hospitalized patients with CAP are now needed.
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